cinacalcet has been researched along with Chronic Kidney Diseases in 105 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (4.76) | 29.6817 |
| 2010's | 82 (78.10) | 24.3611 |
| 2020's | 18 (17.14) | 2.80 |
| Authors | Studies |
|---|---|
| Areepium, N; Auamnoy, T; Eiam-Ong, S; Katavetin, P; Ngamkam, J; Praditpornsilpa, K; Susantitaphong, P; Takkavatakarn, K; Tiranathanagul, K; Vadcharavivad, S | 1 |
| Chon, Y; Drayer, D; Goodman, WG; Lai, J; Martin, KJ; Moore, C; Nemeth, EF; Ward, DT; Xu, J | 1 |
| Choi, B; Han, S; Jung, JH; Kim, H; Lee, MJ; Park, C; Park, I; Park, RW; Shin, DH; Shin, GT; Son, M | 1 |
| Idasiak-Piechocka, I; Lacka, K; Miedziaszczyk, M; Wiśniewski, OW | 1 |
| Cao, Y; Sun, H; Wang, Z; Xiong, Y | 1 |
| Bacchetta, J; Bernardor, J; De Mul, A; Schmitt, CP | 1 |
| Cheung, SC; Lang, BH; Lo, WK; Tang, TK; Wang, AY; Yau, YY | 1 |
| Bakhle, D; Bhonde, M; Chaudhari, VD; Gandhe, A; Ghodke, R; Goel, R; Gote, G; Gundu, J; Kamboj, RK; Khan, T; Kulkarni, S; Loriya, R; Mahajan, N; Mehta, M; Modak, V; Modi, D; Narasimham, L; Nigade, P; Pachpute, V; Palle, VP; Patil, V; Pawar, C; Pawar, S; Phadtare, R; Sabde, S; Sadasivam, G; Sarde, A; Sayyed, M; Shah, C; Sharma, S; Shukla, MR; Tryambake, M; Walke, N | 1 |
| Fuertinger, DH; Kotanko, P; Schappacher-Tilp, G | 1 |
| Centeno, PP; Chavez-Abiega, S; Elajnaf, T; Goedhart, J; Kallay, E; Mos, I; Schlattl, W; Ward, DT | 1 |
| Brandenburg, VM; Kramann, R; Schuh, A | 1 |
| Bacchetta, J; Bloss, L; Mo, M; Ng, E; Schaefer, F; Warady, BA | 1 |
| Al-Ahmad, RA; Alhasan, KA; Kari, JA; Sheerah, AA | 1 |
| Johnson, DW; Mavridis, D; Palmer, SC; Ruospo, M; Strippoli, GFM; Tonelli, M | 1 |
| Endo, Y; Fukagawa, M; Hamano, N; Kawata, T | 1 |
| Choukroun, G; Couchoud, C; Jacquelinet, C; Lambert, O; Mercadal, L; Metzger, M | 1 |
| Fomenko, MS; Pavlov, AA; Sheng, Z; Shilenko, PA; Shneider, YA; Sun, Y; Tian, B; Tsoi, MD; Wan, P; Xu, T; Yao, L | 1 |
| Chang, JF; Chiu, IJ; Hsieh, CY; Hsu, YH; Hung, KC; Hung, LY; Lu, KC; Syu, RS; Wang, TM; Wu, CC; Wu, MS; Wu, MY; Zheng, CM | 1 |
| Bachmeyer, C; Belaube, N; Gauthé, M; Haymann, JP; Loi, V; Wendum, D | 1 |
| Cai, L; Fang, W; He, X; Li, X; Wang, X; Wu, H; Xu, X; Zhang, Z | 1 |
| Dulfer, RR; Franssen, GJH; Hesselink, DA; Hoorn, EJ; van Eijck, CHJ; van Ginhoven, TM | 1 |
| Sin, HY | 1 |
| Brown, AJ; Coyne, DW; Gupta, D; Miller, B; Ritter, C; Slatopolsky, E; Zheng, S | 1 |
| Bi, J; Enoki, Y; Fujimura, R; Fukagawa, M; Hirata, K; Ikegami, K; Imafuku, T; Ishima, Y; Jingami, S; Komaba, H; Maeda, H; Maruyama, T; Matsushita, K; Murata, M; Nishida, K; Otagiri, M; Sakaguchi, Y; Sugimoto, R; Tanaka, M; Watanabe, H | 1 |
| Dryl-Rydzyńska, T; Marcinkowski, W; Małyszko, J; Małyszko, JS; Prystacki, T; Zawierucha, J | 1 |
| Eräranta, A; Lakkisto, P; Mustonen, J; Niemelä, O; Paavonen, T; Pörsti, I; Tikkanen, I; Törmänen, S | 1 |
| Bover, J; Cohen-Solal, M; Ureña Torres, PA | 1 |
| Cozzolino, M | 1 |
| Barany, P; Birnie, K; Carrero, JJ; Caskey, FJ; Evans, M; Gasparini, A; MacNeill, S; May, MT; Methven, S | 1 |
| La Manna, G | 1 |
| Gu, W; Ji, X; Liu, H; Mu, Y; Wang, C; Wang, G | 1 |
| Akizawa, T; Fukagawa, M; Haruyama, W; Hisada, Y; Kawata, T; Masuda, N; Miyazaki, H; Murai, M; Shoukei, Y; Tokunaga, S; Wada, M; Yanagida, T | 1 |
| Belozeroff, V; Bennett, H; Bensink, ME; Block, GA; Chertow, GM; Cooper, K; Goring, S; Levy, AR; Lozano-Ortega, G; Trotman, ML; Waser, N | 1 |
| Bellasi, A; Cancarini, G; Cozzolino, M; Esposito, C; Genderini, A; Guastoni, CM; Locatelli, F; Malberti, F; Messa, P; Ondei, P; Pontoriero, G; Teatini, U; Vezzoli, G | 1 |
| Adamczak, M; Kuczera, P; Machnik, G; Okopien, B; Wiecek, A | 2 |
| Hamano, T | 1 |
| Hu, SL; Joshi, P; Kaplan, M; Lefkovitz, J; Michaud, DS | 1 |
| Akizawa, T; Fukagawa, M; Shimazaki, R | 1 |
| Akizawa, T; Fukagawa, M; Shimazaki, R; Shiramoto, M | 1 |
| Ariceta, G; Dehmel, B; Hidalgo, G; Iles, JN; Jiang, X; Laskin, B; Schaefer, F; Shahinfar, S; Vande Walle, J; Warady, BA | 1 |
| Deen, J; Schaider, H | 1 |
| Chen, P; Gisleskog, PO; Melhem, M; Narayanan, A; Sohn, W | 1 |
| Mazzaferro, S; Pasquali, M | 1 |
| Chang, TJ; Chiu, HW; Hsu, YH; Lin, YF; Liu, WC; Lu, CL; Lu, KC; Shyu, JF; Wu, CC; Zheng, CM; Zheng, JQ | 1 |
| Fukagawa, M; Kakuta, T; Komaba, H | 1 |
| Chen, TC; Chiu, TT; Kuo, CC; Lee, CT; Lee, WC; Lee, YT; Ng, HY; Wu, CS | 1 |
| Covic, A; Craig, JC; Messa, P; Nistor, I; Palmer, SC; Pellegrini, F; Strippoli, GF; Tonelli, M | 1 |
| Ito, M; Koshika, M; Kudo, K; Masakane, I; Nishida, H; Nishida, W; Tanida, H; Tomita, Y | 1 |
| Adamczak, M; Kuczera, P; Więcek, A | 3 |
| Moe, SM; Thadhani, R | 1 |
| Adema, AY; de Borst, MH; Ter Wee, PM; Vervloet, MG | 1 |
| Grzegorzewska, AE; Ostromecki, G | 1 |
| Biggar, P; Graf, H; Ketteler, M; Klauser-Braun, R; Kovarik, J; Müller, HW; Seidinger, S; Veres, A | 1 |
| Cozzolino, M; Goldsmith, D; Ketteler, M; Khan, S; Martin, KJ; Sharma, A | 1 |
| Covic, A; Goldsmith, D | 1 |
| Howell, BL; Powers, CA; St Peter, WL; Yusuf, AA | 1 |
| Behets, GJ; D'Haese, PC; De Broe, ME; Goodman, WG; Spasovski, G; Spiegel, DM; Sterling, LR | 1 |
| Abdelrahman, M; Abdulkader, M; Algareeb, A; Awn, NM; Karkar, A; Mushtaque, F; Nassar, M; Qadi, Y; Sabry, A; Shaheen, FA; Sinha, AK; Souqiyyeh, MZ; Taha, MI | 1 |
| Hénaut, L; Larsson, TE; Massy, ZA; Vervloet, MG | 1 |
| Andreucci, VE; Bieber, BA; Frimat, L; Fukagawa, M; Jacobson, SH; Karaboyas, A; Li, Y; Mendelssohn, DC; Pisoni, RL; Port, FK; Robinson, BM; Tentori, F; Wang, M | 1 |
| Abukhatwah, MW; Alharthi, AA; Kamal, NM; Sherief, LM | 1 |
| Yokoyama, K | 1 |
| Covic, A; Cozzolino, M; Goldsmith, D; Nistor, I; Vervloet, M | 1 |
| Inaba, M | 1 |
| Lhotta, K; Mündle, M; Sprenger-Mähr, H; Zitt, E | 1 |
| Block, GA; Chertow, GM; Correa-Rotter, R; Drüeke, TB; Floege, J; Herzog, CA; London, GM; Mahaffey, KW; Moe, SM; Parfrey, PS; Wheeler, DC | 1 |
| Busse, JW; Guyatt, GH; Mustafa, RA; Sekercioglu, N; Thabane, L | 1 |
| Ito, T; Iwashita, Y; Shigematsu, T | 1 |
| Kadokura, Y; Kakuta, T; Nakamura, M; Tahara, H; Tominaga, Y; Yasunaga, C | 1 |
| Akizawa, T; Alan Brookhart, M; Ellis, AR; Fukagawa, M; Fukuhara, S; Fukuma, S; Hasegawa, T; Kurita, N; Kurokawa, K; Mizobuchi, M; Onishi, Y; Yamaguchi, T | 1 |
| Ballarin, J; Bover, J; DaSilva, I; Diaz-Encarnacion, MM; Fernández, E; Lloret, MJ; Mateu, S; Mercado, C; Ruiz, C; Ureña-Torres, P | 1 |
| Chen, L; Duan, W; Lai, L; Wang, K; Yu, S; Yuan, J; Zhang, X | 1 |
| Buttar, RS; Coco, M; Melamed, ML | 1 |
| Dryl-Rydzyńska, T; Marcinkowski, W; Małyszko, J; Prystacki, T; Zawierucha, J | 1 |
| Alcalde-Rodrigo, M; Galicia-Basart, M; Montoro-Ronsano, JB; Pérez-Ricart, A; Segarra-Medrano, A; Suñé-Negre, JM | 1 |
| Chazot, C; Deleaval, P; Hurot, JM; Jean, G; Lorriaux, C; Mayor, B; Mehdi, M; Souberbielle, JC; Zaoui, E | 1 |
| Bock, A; Hemetsberger, M; Jäger, C; Klauser-Braun, R; Lhotta, K; Pendl, G; Pronai, W; Rosenkranz, AR | 1 |
| Brancaccio, D; Ciceri, P; Cozzolino, M; Fallabrino, G; Gallieni, M; Olivi, L; Pasho, S; Volpi, EM | 1 |
| Finch, JL; Lane, N; Nakamura, H; Shahnazari, M; Slatopolsky, E; Tokumoto, M; Yao, W | 1 |
| Goltzman, D | 1 |
| Klein, GL | 1 |
| Chiroli, S; Eandi, M; Iannazzo, S; Pontoriero, G; Pradelli, L | 1 |
| Brzosko, S; Hryszko, T; Koc-Zorawska, E; Mysliwiec, M; Rydzewska-Rosolowska, A | 1 |
| Mehls, O; Schmitt, CP | 1 |
| Youssef, D | 1 |
| Amdahl, M; Cozzolino, M; Goldsmith, D; Ketteler, M; Khan, S; Martin, KJ; Marx, S; Sharma, A; Wolf, M | 1 |
| Hu, B; Hu, P; Lu, L; Qin, YH; Wang, J; Xuan, Q | 1 |
| Fathallah-Shaykh, S; Langman, CB; Lee, E; Padhi, D; Posvar, E; Salusky, IB; Wang, C; Warady, BA | 1 |
| Brancaccio, D; Cannella, G; Cornago, D; Costanzo, AM; Cozzolino, M; Di Luca, M; di Luzio Paparatti, U; Mazzaferro, S; Messa, P; Morosetti, M; Roggeri, DP | 1 |
| Akizawa, T; Fukagawa, M; Fukuhara, S; Fukuma, S; Hasegawa, T; Kurokawa, K; Onishi, Y; Yamaguchi, T | 1 |
| Akiba, T; Kikuchi, K; Nitta, K; Okano, K; Tsuruta, Y | 1 |
| Cai, MM; Holt, SG; McMahon, LP; Smith, ER; Williams, DS | 1 |
| Ando, T; Ito, K; Nagano, N; Yoshitaka, A | 1 |
| Barros, X; Campistol, JM; Durán, CE; Paschoalin, RP; Soler, M; Torregrosa, JV | 1 |
| Floege, J; Goodman, WG; Hawley, CM; Pedagogos, E; Pétavy, F; Raggi, P; Reiner, M; Ureña-Torres, PA | 1 |
| Goldsmith, D; Leonard, O; Spaak, J | 1 |
| Barco, S; Cangemi, G; Della Casa Alberighi, O; Melioli, G; Scurati, S; Verrina, EE | 1 |
| Bridges, I; Christiano, C; Cooper, K; Cournoyer, SH; Covic, A; Farouk, M; Kopyt, NP; Rodriguez, M; Ureña-Torres, P; Zehnder, D | 1 |
| Argilés, A; Chong, G; Deleuze, S; Delmas, S; Garrigue, V; Mourad, G; Szwarc, I | 1 |
| Harris, RZ; Padhi, D; Salfi, M; Sullivan, JT | 1 |
| Joy, MS; Karagiannis, PC; Peyerl, FW | 1 |
| Akizawa, T; Kinugasa, E; Koiwa, F; Ogata, H | 1 |
33 review(s) available for cinacalcet and Chronic Kidney Diseases
| Article | Year |
|---|---|
A systematic review of the pharmacotherapy of secondary hyperparathyroidism (SHPT) in grades 3-5 Chronic Kidney Disease (CKD).
Topics: Calcitriol; Calcium; Cinacalcet; Ergocalciferols; Humans; Hyperparathyroidism, Secondary; Parathyroid Hormone; Renal Dialysis; Renal Insufficiency, Chronic | 2022 |
Impact of Cinacalcet and Etelcalcetide on Bone Mineral and Cardiovascular Disease in Dialysis Patients.
Topics: Adult; Calcimimetic Agents; Calcium; Cardiovascular Diseases; Child; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Minerals; Parathyroid Hormone; Phosphates; Renal Dialysis; Renal Insufficiency, Chronic; Vitamin D | 2023 |
Sensing Extracellular Calcium - An Insight into the Structure and Function of the Calcium-Sensing Receptor (CaSR).
Topics: Calcium; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney; Parathyroid Glands; Receptors, Calcium-Sensing; Renal Insufficiency, Chronic | 2020 |
Valvular Calcification in Chronic Kidney Disease.
Topics: Aortic Valve; Aortic Valve Stenosis; Calcinosis; Calcium-Regulating Hormones and Agents; Chelating Agents; Cinacalcet; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Renal Insufficiency, Chronic; Sevelamer; Transcatheter Aortic Valve Replacement; Vitamin K | 2019 |
Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis.
Topics: Adolescent; Calcimimetic Agents; Child; Child, Preschool; Cinacalcet; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Double-Blind Method; Equivalence Trials as Topic; Female; Humans; Hyperparathyroidism, Secondary; Male; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic | 2020 |
Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
Topics: Adult; Calcimimetic Agents; Calcium; Cardiovascular Diseases; Cinacalcet; Comorbidity; Female; Fractures, Bone; Heart Failure; Humans; Hyperparathyroidism, Secondary; Male; Mortality; Naphthalenes; Nausea; Parathyroid Hormone; Peptides; Pyrrolidines; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome; Vomiting | 2020 |
Development of evocalcet for unmet needs among calcimimetic agents.
Topics: Calcimimetic Agents; Calcium; Cinacalcet; Gastrointestinal Diseases; Humans; Hyperparathyroidism, Secondary; Japan; Naphthalenes; Phosphorus; Pyrrolidines; Receptors, Calcium-Sensing; Renal Dialysis; Renal Insufficiency, Chronic | 2020 |
[Aortic valve replacement via J-shaped partial upper sternotomy: randomized trial, mid-term results].
Topics: Adult; Aged; Aortic Valve; Calcium-Regulating Hormones and Agents; Cinacalcet; Female; Heart Valve Diseases; Heart Valve Prosthesis Implantation; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Minimally Invasive Surgical Procedures; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Retrospective Studies; Sternotomy; Treatment Outcome | 2020 |
Systematic review of surgical and medical treatment for tertiary hyperparathyroidism.
Topics: Calcimimetic Agents; Cinacalcet; Graft Survival; Humans; Hyperparathyroidism, Secondary; Kidney Transplantation; Parathyroidectomy; Postoperative Complications; Renal Insufficiency, Chronic | 2017 |
Cinacalcet versus Placebo for secondary hyperparathyroidism in chronic kidney disease patients: a meta-analysis of randomized controlled trials and trial sequential analysis.
Topics: Calcimimetic Agents; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic | 2018 |
Effects of calcimimetics on long-term outcomes in dialysis patients: literature review and Bayesian meta-analysis.
Topics: Adult; Aged; Bayes Theorem; Calcimimetic Agents; Cinacalcet; Female; Fractures, Spontaneous; Hospitalization; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Observational Studies as Topic; Parathyroidectomy; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome | 2018 |
Mineral and bone disorders in conventional hemodialysis: Challenges and solutions.
Topics: Bone Density; Bone Density Conservation Agents; Calcium; Calcium-Regulating Hormones and Agents; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Fractures, Bone; Humans; Parathyroid Hormone; Phosphates; Renal Dialysis; Renal Insufficiency, Chronic; Vascular Calcification | 2018 |
The use of cinacalcet for the treatment of calciphylaxis in patients with chronic kidney disease: A comprehensive review.
Topics: Calciphylaxis; Calcium-Regulating Hormones and Agents; Cinacalcet; Combined Modality Therapy; Humans; Renal Insufficiency, Chronic | 2019 |
Hyperparathyroidism in chronic kidney disease patients: an update on current pharmacotherapy.
Topics: Bone and Bones; Calcimimetic Agents; Chelating Agents; Cinacalcet; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Medication Adherence; Naphthalenes; Receptors, Calcitriol; Renal Insufficiency, Chronic; Vitamin D | 2013 |
Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials.
Topics: Calcimimetic Agents; Calcium Metabolism Disorders; Cardiovascular Diseases; Cinacalcet; Humans; Hyperparathyroidism; Naphthalenes; Nausea; Parathyroid Hormone; Parathyroidectomy; Renal Insufficiency, Chronic; Vomiting | 2013 |
What have we learned about chronic kidney disease-mineral bone disorder from the EVOLVE and PRIMO trials?
Topics: Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcimimetic Agents; Cardiovascular Diseases; Cinacalcet; Ergocalciferols; Humans; Hyperparathyroidism, Secondary; Naphthalenes; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic | 2013 |
Dietary and pharmacological modification of fibroblast growth factor-23 in chronic kidney disease.
Topics: Calcium; Calcium, Dietary; Cardiovascular Diseases; Chelating Agents; Cinacalcet; Diet; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Lanthanum; Naphthalenes; Phosphorus; Phosphorus, Dietary; Polyamines; Renal Insufficiency, Chronic; Sevelamer | 2014 |
[Gene polymorphism of the vitamin D receptor, vitamin D-binding protein and calcium-sensing receptor in respect of calcium-phosphate disturbances in chronic dialysis patients].
Topics: Calcium; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Naphthalenes; Phosphates; Polymorphism, Genetic; Receptors, Calcitriol; Receptors, Calcium-Sensing; Renal Dialysis; Renal Insufficiency, Chronic; Vitamin D-Binding Protein | 2013 |
Calcium-sensing receptor activation in chronic kidney disease: effects beyond parathyroid hormone control.
Topics: Bone and Bones; Calcimimetic Agents; Cinacalcet; Gastrointestinal Tract; Homeostasis; Humans; Hyperparathyroidism, Secondary; Hypertension, Pulmonary; Naphthalenes; Parathyroid Hormone; Receptors, Calcium-Sensing; Renal Insufficiency, Chronic; Signal Transduction; Vascular Calcification; Water-Electrolyte Balance | 2014 |
[Vascular Calcification - Pathological Mechanism and Clinical Application - . The effect of cinacalcet on vascular calcification].
Topics: Animals; Calcimimetic Agents; Cardiovascular Diseases; Cinacalcet; Disease Progression; Humans; Naphthalenes; Randomized Controlled Trials as Topic; Receptors, Calcium-Sensing; Renal Insufficiency, Chronic; Vascular Calcification | 2015 |
Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis.
Topics: Calcimimetic Agents; Cardiovascular Diseases; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Research Design; Risk Factors; Treatment Outcome | 2016 |
Cinacalcet versus standard treatment for chronic kidney disease: a protocol for a systematic review and meta-analysis.
Topics: Calcimimetic Agents; Cinacalcet; Diet; Humans; Parathyroid Hormone; Phosphate-Binding Proteins; Renal Insufficiency, Chronic; Systematic Reviews as Topic; Treatment Outcome; Vitamin D | 2016 |
[Treatment for CKD-MBD(Chronic Kidney Disease-Mineral and Bone Disorder)].
Topics: Bone and Bones; Bone Diseases, Metabolic; Calcimimetic Agents; Calcinosis; Calcium Carbonate; Cardiovascular Diseases; Cinacalcet; Ferric Compounds; Fractures, Bone; Humans; Minerals; Parathyroidectomy; Phosphates; Phosphorus, Dietary; Renal Insufficiency, Chronic; Risk Factors; Sevelamer | 2016 |
Integral pharmacological management of bone mineral disorders in chronic kidney disease (part II): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.
Topics: Bone Diseases, Metabolic; Cinacalcet; Disease Progression; Humans; Hyperparathyroidism, Secondary; Minerals; Phosphates; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Vitamin D | 2016 |
Long-term mortality after parathyroidectomy among chronic kidney disease patients with secondary hyperparathyroidism: a systematic review and meta-analysis.
Topics: Calcimimetic Agents; Calcium; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Parathyroid Hormone; Parathyroidectomy; Prospective Studies; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Survival Rate; Treatment Outcome | 2016 |
CKD-Mineral Bone Disorder in Stage 4 and 5 CKD: What We Know Today?
Topics: Bicarbonates; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Diet, Protein-Restricted; Fibroblast Growth Factor-23; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Parathyroid Hormone; Phosphates; Renal Insufficiency, Chronic; Vitamin D | 2016 |
Management of secondary hyperparathyroidism in the elderly patient with chronic kidney disease.
Topics: Aged; Chelating Agents; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Naphthalenes; Parathyroid Hormone; Parathyroidectomy; Phosphates; Practice Guidelines as Topic; Receptors, Calcitriol; Renal Insufficiency, Chronic | 2009 |
Mineral and bone disorders in children with chronic kidney disease.
Topics: Child; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Homeostasis; Humans; Minerals; Naphthalenes; Renal Insufficiency, Chronic | 2011 |
Fibroblast growth factor-23 helps explain the biphasic cardiovascular effects of vitamin D in chronic kidney disease.
Topics: Animals; Calcimimetic Agents; Cardiovascular Diseases; Chelating Agents; Cinacalcet; Diet; Endothelium, Vascular; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperparathyroidism, Secondary; Hypertrophy, Left Ventricular; Kidney Failure, Chronic; Kidney Transplantation; Male; Naphthalenes; Parathyroid Hormone; Phosphates; Polyamines; Renal Insufficiency, Chronic; Sevelamer; Vascular Calcification; Vitamin D; Vitamin D Deficiency | 2012 |
[Cinacalcet hydrochloride and phosphate metabolism].
Topics: Animals; Calcium; Cinacalcet; Humans; Naphthalenes; Parathyroid Glands; Parathyroid Hormone; Phosphorus; Renal Dialysis; Renal Insufficiency, Chronic | 2012 |
Regression of vascular calcification in chronic kidney disease - feasible or fantasy? a review of the clinical evidence.
Topics: Animals; Calcium; Cardiovascular Diseases; Cinacalcet; Humans; Naphthalenes; Phosphates; Primary Prevention; Renal Dialysis; Renal Insufficiency, Chronic; Secondary Prevention; Vascular Calcification | 2013 |
Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.
Topics: Calcitriol; Cardiovascular Diseases; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Cost-Benefit Analysis; Drug Costs; Ergocalciferols; Humans; Hyperparathyroidism, Secondary; Naphthalenes; Parathyroid Hormone; Parathyroidectomy; Renal Insufficiency, Chronic; Vitamin D; Vitamins | 2007 |
CKD-MBD: impact on management of kidney disease.
Topics: Aniline Compounds; Bone Diseases, Metabolic; Calcium Metabolism Disorders; Cardiovascular Diseases; Chelating Agents; Cinacalcet; Disease Progression; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Lanthanum; Naphthalenes; Phenethylamines; Polyamines; Propylamines; Renal Insufficiency, Chronic; Sevelamer; Vitamin D; Vitamin D Deficiency; Vitamins | 2007 |
15 trial(s) available for cinacalcet and Chronic Kidney Diseases
| Article | Year |
|---|---|
Parathyroidectomy versus oral cinacalcet on cardiovascular parameters in peritoneal dialysis patients with advanced secondary hyperparathyroidism (PROCEED): a randomized trial.
Topics: Adult; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Parathyroidectomy; Peritoneal Dialysis; Prospective Studies; Quality of Life; Renal Dialysis; Renal Insufficiency, Chronic | 2023 |
[Aortic valve replacement via J-shaped partial upper sternotomy: randomized trial, mid-term results].
Topics: Adult; Aged; Aortic Valve; Calcium-Regulating Hormones and Agents; Cinacalcet; Female; Heart Valve Diseases; Heart Valve Prosthesis Implantation; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Minimally Invasive Surgical Procedures; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Retrospective Studies; Sternotomy; Treatment Outcome | 2020 |
Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism.
Topics: Aged; Calcimimetic Agents; Cinacalcet; Double-Blind Method; Female; Gastrointestinal Diseases; Humans; Hyperparathyroidism, Secondary; Japan; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Pyrrolidines; Renal Dialysis; Renal Insufficiency, Chronic | 2018 |
Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study.
Topics: Adult; Area Under Curve; Asian People; Calcimimetic Agents; Cinacalcet; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Hyperparathyroidism, Secondary; Male; Renal Insufficiency, Chronic; Single-Blind Method | 2018 |
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis.
Topics: Adolescent; Calcimimetic Agents; Calcium; Child; Cinacalcet; Double-Blind Method; Female; Humans; Hyperparathyroidism, Secondary; Hypertension; Hypocalcemia; Male; Nausea; Parathyroid Hormone; Placebos; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome; Vitamin D; Vomiting | 2019 |
Cinacalcet treatment decreases plasma fibroblast growth factor 23 concentration in haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism.
Topics: Adult; Calcium; Cinacalcet; Depression, Chemical; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphates; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic | 2014 |
Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.
Topics: Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Cinacalcet; Dose-Response Relationship, Drug; Ergocalciferols; Female; Fibroblast Growth Factor-23; Follow-Up Studies; Humans; Hyperparathyroidism, Secondary; Injections, Intravenous; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome | 2014 |
Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Bone Diseases, Metabolic; Bone Resorption; Calcimimetic Agents; Calcium; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Osteogenesis; Parathyroid Hormone; Renal Dialysis; Renal Insufficiency, Chronic; Time Factors; Young Adult | 2015 |
PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism.
Topics: Aged; Calcimimetic Agents; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Parathyroid Hormone; Renal Dialysis; Renal Insufficiency, Chronic | 2016 |
Cinacalcet lowers FGF-23 level together with bone metabolism in hemodialyzed patients with secondary hyperparathyroidism.
Topics: Aged; Bone and Bones; Calcimimetic Agents; Cinacalcet; Collagen Type I; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Osteoblasts; Osteocalcin; Parathyroid Hormone; Peptides; Renal Dialysis; Renal Insufficiency, Chronic | 2012 |
Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study.
Topics: Administration, Intravenous; Administration, Oral; Aged; Bone Density; Bone Density Conservation Agents; Calcium; Cinacalcet; Drug Therapy, Combination; Ergocalciferols; Female; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Receptors, Calcitriol; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome; Vitamin D | 2012 |
An open-label study to evaluate a single-dose of cinacalcet in pediatric dialysis subjects.
Topics: Administration, Oral; Adolescent; Age Factors; Area Under Curve; Biomarkers; Body Surface Area; Calcimimetic Agents; Calcium; Child; Cinacalcet; Drug Dosage Calculations; Female; Humans; Hyperparathyroidism, Secondary; Male; Naphthalenes; Parathyroid Hormone; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome; United States | 2012 |
Protocol adherence and the progression of cardiovascular calcification in the ADVANCE study.
Topics: Aged; Cinacalcet; Disease Progression; Female; Humans; Hyperparathyroidism, Secondary; Male; Medication Adherence; Middle Aged; Naphthalenes; Renal Dialysis; Renal Insufficiency, Chronic; Vascular Calcification; Vitamin D | 2013 |
Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism.
Topics: Adult; Aged; Calcium; Case-Control Studies; Cinacalcet; Cohort Studies; Female; Follow-Up Studies; Humans; Hyperparathyroidism, Secondary; International Agencies; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Prognosis; Renal Dialysis; Renal Insufficiency, Chronic; Vitamin D; Vitamins | 2013 |
Pharmacokinetics of cinacalcet hydrochloride when administered with ketoconazole.
Topics: Administration, Oral; Adult; Analysis of Variance; Antifungal Agents; Area Under Curve; Calcium; Cinacalcet; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Administration Schedule; Drug Interactions; Female; Half-Life; Humans; Hyperparathyroidism, Secondary; Ketoconazole; Male; Naphthalenes; Renal Insufficiency, Chronic | 2007 |
58 other study(ies) available for cinacalcet and Chronic Kidney Diseases
| Article | Year |
|---|---|
The impact of CASR A990G polymorphism in response to cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism.
Topics: Age Factors; Aged; Alleles; Calcitriol; Calcium; Calcium-Regulating Hormones and Agents; Cinacalcet; Ergocalciferols; Female; Gene Expression; Genotype; Heterozygote; Homozygote; Humans; Hyperparathyroidism, Secondary; Logistic Models; Male; Middle Aged; Parathyroid Hormone; Phosphates; Polymorphism, Single Nucleotide; Receptors, Calcium-Sensing; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies | 2021 |
Activation of the Calcium Receptor by Calcimimetic Agents Is Preserved Despite Modest Attenuating Effects of Hyperphosphatemia.
Topics: Aged; Calcimimetic Agents; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Male; Middle Aged; Parathyroid Hormone; Peptides; Phosphorus; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies | 2022 |
Characterization of Medication Trends for Chronic Kidney Disease: Mineral and Bone Disorder Treatment Using Electronic Health Record-Based Common Data Model.
Topics: Adult; Aged; Aged, 80 and over; Calcium-Regulating Hormones and Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Electronic Health Records; Female; Hospitals, University; Humans; Male; Middle Aged; Practice Guidelines as Topic; Receptors, Calcitriol; Renal Insufficiency, Chronic; Republic of Korea; Retrospective Studies; Tertiary Care Centers | 2021 |
Neurorescuing effect of Cinacalcet against hypercalcemia-induced nerve injury in chronic kidney disease via TRAF2/cIAP1/KLF2/SERPINA3 signal axis.
Topics: Animals; Cinacalcet; Hypercalcemia; Mice; Renal Insufficiency, Chronic; TNF Receptor-Associated Factor 2; Ubiquitin | 2023 |
Discovery of LNP1892: A Precision Calcimimetic for the Treatment of Secondary Hyperparathyroidism.
Topics: Animals; Calcium; Cinacalcet; Hyperparathyroidism, Secondary; Naphthalenes; Parathyroid Hormone; Renal Insufficiency, Chronic | 2023 |
A Multi-Compartment Model Capturing the Pharmacokinetics of the Calcimimetic Cinacalcet.
Topics: Calcimimetic Agents; Cinacalcet; Computer Simulation; Humans; Hyperparathyroidism, Secondary; Liver; Models, Biological; Protein Binding; Renal Insufficiency, Chronic | 2019 |
Cinacalcet use in pediatric chronic kidney disease. A survey study.
Topics: Age Factors; Bone Diseases, Metabolic; Child; Child, Preschool; Cinacalcet; Female; Humans; Hyperparathyroidism; Infant; Male; Practice Guidelines as Topic; Renal Insufficiency, Chronic; Surveys and Questionnaires; Treatment Outcome | 2020 |
Effects of the dialysate calcium concentrations and mineral bone disease treatments on mortality in The French Renal Epidemiology and Information Network (REIN) registry.
Topics: Aged; Blood Vessels; Bone and Bones; Calcinosis; Calcium; Cinacalcet; Female; France; Hemodialysis Solutions; Humans; Lanthanum; Longitudinal Studies; Male; Middle Aged; Proportional Hazards Models; Registries; Renal Dialysis; Renal Insufficiency, Chronic; Sevelamer; Vitamin D | 2020 |
Therapeutic Effect of Calcimimetics on Osteoclast-Osteoblast Crosslink in Chronic Kidney Disease and Mineral Bone Disease.
Topics: Adult; Aged; Biomarkers; Bone Density; Bone Diseases; Bone Resorption; Calcimimetic Agents; Cinacalcet; Female; Humans; Male; Middle Aged; Osteoblasts; Osteoclasts; Osteogenesis; Outcome Assessment, Health Care; Parathyroid Hormone; Renal Dialysis; Renal Insufficiency, Chronic; Tartrate-Resistant Acid Phosphatase | 2020 |
Hypercalcemia and Acute Renal Failure Indicating Peritoneal Sarcoidosis.
Topics: Acute Kidney Injury; Aged, 80 and over; Calcium-Regulating Hormones and Agents; Cinacalcet; Diagnosis, Differential; Glucocorticoids; Humans; Hypercalcemia; Laparoscopy; Lymphadenopathy; Male; Peritoneal Diseases; Peritonitis, Tuberculous; Positron Emission Tomography Computed Tomography; Prednisone; Renal Insufficiency, Chronic; Sarcoidosis; Tomography, X-Ray Computed | 2021 |
Paricalcitol versus Calcitriol + Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease in China: A Cost-Effectiveness Analysis.
Topics: Calcitriol; Cinacalcet; Cost-Benefit Analysis; Ergocalciferols; Humans; Hyperparathyroidism, Secondary; Quality of Life; Renal Dialysis; Renal Insufficiency, Chronic | 2021 |
Prospective cohort study: Cinacalcet-mediated lowering of PTH level and cardiovascular disease mortality in younger Korean patients with stage 5 CKD at a Korean secondary hospital.
Topics: Adolescent; Adult; Age Factors; Aged; Asian People; Calcimimetic Agents; Cardiovascular Diseases; Cinacalcet; Cohort Studies; Female; Glomerular Filtration Rate; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Parathyroid Hormone; Prospective Studies; Renal Insufficiency, Chronic; Republic of Korea; Young Adult | 2017 |
Paricalcitol and cinacalcet have disparate actions on parathyroid oxyphil cell content in patients with chronic kidney disease.
Topics: Adult; Calcimimetic Agents; Calcitriol; Cell Transdifferentiation; Cinacalcet; Drug Therapy, Combination; Ergocalciferols; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Oxyphil Cells; Parathyroid Glands; Parathyroidectomy; Receptors, Calcium-Sensing; Renal Insufficiency, Chronic; Uremia; Vitamin D | 2017 |
Parathyroid hormone contributes to the down-regulation of cytochrome P450 3A through the cAMP/PI3K/PKC/PKA/NF-κB signaling pathway in secondary hyperparathyroidism.
Topics: Animals; Caco-2 Cells; Cinacalcet; Cyclic AMP; Cytochrome P-450 CYP3A; Down-Regulation; GABA Modulators; Gene Expression Regulation, Enzymologic; Hepatocytes; Humans; Hyperparathyroidism; Male; Midazolam; NF-kappa B; Parathyroid Hormone; Phosphatidylinositol 3-Kinases; Protein Kinase C; Random Allocation; Rats; Renal Insufficiency, Chronic; Signal Transduction | 2017 |
Treatment of secondary hyperparathyroidism with paricalcitol with or without cinacalcet in hemodialysis patients.
Topics: Adult; Aged; Calcium-Regulating Hormones and Agents; Cinacalcet; Drug Therapy, Combination; Ergocalciferols; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome | 2017 |
Endothelin A receptor blocker and calcimimetic in the adenine rat model of chronic renal insufficiency.
Topics: Adenine; Animals; Calcimimetic Agents; Cinacalcet; Disease Models, Animal; Endothelin A Receptor Antagonists; Isoxazoles; Male; Rats; Rats, Wistar; Renal Insufficiency, Chronic; Thiophenes | 2017 |
Etelcalcetide: injectable calcimimetic for the treatment of secondary hyperparathyroidism in hemodialysis-dependent patients.
Topics: Animals; Cinacalcet; Fibroblast Growth Factor-23; Humans; Hyperparathyroidism, Secondary; Medication Adherence; Parathyroid Hormone; Peptides; Renal Dialysis; Renal Insufficiency, Chronic | 2017 |
Achieve Your Goals Together. The Easy and Reasonable Way to Treat Chronic Kidney Disease-Mineral Bone Disorder.
Topics: Calcitriol; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Goals; Humans; Hyperparathyroidism, Secondary; Minerals; Renal Dialysis; Renal Insufficiency, Chronic | 2018 |
Cinacalcet use and the risk of cardiovascular events, fractures and mortality in chronic kidney disease patients with secondary hyperparathyroidism.
Topics: Aged; Calcimimetic Agents; Cardiovascular Diseases; Cinacalcet; Female; Fractures, Bone; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Renal Dialysis; Renal Insufficiency, Chronic; Sweden | 2018 |
Parathyroidectomy Before or After Transplantation: A Dilemma Still Open!
Topics: Calcimimetic Agents; Cinacalcet; Humans; Hyperparathyroidism; Kidney Transplantation; Parathyroidectomy; Renal Insufficiency, Chronic | 2018 |
A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro.
Topics: Administration, Oral; Animals; Calcimimetic Agents; Callithrix; Cinacalcet; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Gastrointestinal Tract; HEK293 Cells; Humans; Isoenzymes; Male; Molecular Structure; Parathyroid Glands; Parathyroid Hormone; Rats, Wistar; Receptors, Calcium-Sensing; Renal Insufficiency, Chronic; Vomiting | 2018 |
[New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of Nephrologists form Lombardy].
Topics: Calcimimetic Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Clinical Trials as Topic; Drug Therapy, Combination; Health Services Needs and Demand; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Parathyroid Glands; Parathyroid Hormone; Peptides; Receptors, Calcium-Sensing; Renal Dialysis; Renal Insufficiency, Chronic; Vitamin D | 2018 |
Treatment Based on Cinacalcet Reduces Oxidative Stress in Hemodialysis Patients with Secondary Hyperparathyroidism.
Topics: Adult; Advanced Oxidation Protein Products; Aged; Calcium; Calcium-Regulating Hormones and Agents; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Oxidative Stress; Parathyroid Hormone; Phosphates; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome | 2018 |
Vitamin D and cinacalcet are associated with increased survival in peritoneal dialysis but not with residual renal function preservation
.
Topics: Cinacalcet; Humans; Hyperphosphatemia; Peritoneal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies; Risk Factors; Vitamin D | 2018 |
Bridging adults and paediatrics with secondary hyperparathyroidism receiving haemodialysis: a pharmacokinetic-pharmacodynamic analysis of cinacalcet.
Topics: Adolescent; Adult; Age Factors; Biomarkers; Calcimimetic Agents; Child; Child, Preschool; Cinacalcet; Computer Simulation; Drug Dosage Calculations; Female; Humans; Hyperparathyroidism, Secondary; Hypocalcemia; Male; Models, Biological; Parathyroid Hormone; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome | 2019 |
Direct bone effects of calcimimetics in chronic kidney disease?
Topics: Animals; Bone Remodeling; Calcium; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Naphthalenes; Parathyroid Hormone; Rats; Receptors, Calcium-Sensing; Renal Insufficiency, Chronic | 2019 |
Osteoclast-Released Wnt-10b Underlies Cinacalcet Related Bone Improvement in Chronic Kidney Disease.
Topics: Animals; Bone Density; Bone Resorption; Calcium-Regulating Hormones and Agents; Cells, Cultured; Cinacalcet; Male; Mice; Mice, Inbred C57BL; Osteoclasts; Renal Insufficiency, Chronic; Wnt Proteins | 2019 |
Comparison between calcitriol and calcitriol plus low-dose cinacalcet for the treatment of moderate to severe secondary hyperparathyroidism in chronic dialysis patients.
Topics: Adult; Aged; Biomarkers; Calcimimetic Agents; Calcitriol; Calcium; Cinacalcet; Drug Therapy, Combination; Female; Guideline Adherence; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphates; Practice Guidelines as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies; Severity of Illness Index; Treatment Outcome; Uremia; Vitamins | 2013 |
Chronic hemodialysis patients without marked elevation of intact parathyroid hormone are also good candidates for early intervention with cinacalcet.
Topics: Adult; Aged; Algorithms; Bone Diseases, Metabolic; Calcimimetic Agents; Calcium; Cinacalcet; Female; Humans; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies; Sterols; Time Factors; Vitamin D | 2013 |
Safety and efficiency of treatment with cinacalcet of haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism.
Topics: Adult; Aged; Calcium; Cinacalcet; Dose-Response Relationship, Drug; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphates; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome | 2013 |
Paricalcitol treatment of secondary hyperparathyroidism in hemodialysis patients: a German-Austrian, single-arm, open-label, prospective, noninterventional, observational study.
Topics: Aged; Alkaline Phosphatase; Austria; Bone Density Conservation Agents; Calcimimetic Agents; Calcium; Cinacalcet; Ergocalciferols; Female; Germany; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic | 2014 |
The EVOLVE study is negative, so what does this 'bitter pill' of disappointment mean now for renal patients?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Calcimimetic Agents; Cardiovascular Diseases; Cinacalcet; Humans; Hyperparathyroidism; Middle Aged; Multicenter Studies as Topic; Naphthalenes; Parathyroid Hormone; Prospective Studies; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Renal Replacement Therapy; Treatment Outcome; Young Adult | 2014 |
Utilization and costs of medications associated with CKD mineral and bone disorder in dialysis patients enrolled in Medicare Part D.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Diseases; Cinacalcet; Drug Utilization; Female; Health Expenditures; Humans; Male; Medicare Part D; Middle Aged; Naphthalenes; Phosphate-Binding Proteins; Poverty; Renal Dialysis; Renal Insufficiency, Chronic; United States; Vitamin D; Young Adult | 2014 |
Trends of elevated parathormone serum titers in hemodialysis patients on intensive therapy for bone disease: a multicenter study.
Topics: Adult; Aged; Biomarkers; Bone Diseases, Metabolic; Chelating Agents; Cinacalcet; Cost-Benefit Analysis; Dietary Supplements; Drug Costs; Female; Humans; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphates; Renal Dialysis; Renal Insufficiency, Chronic; Saudi Arabia; Time Factors; Treatment Outcome; Up-Regulation; Vascular Calcification; Vitamin D | 2014 |
Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study.
Topics: Adult; Aged; Biomarkers; Calcimimetic Agents; Cinacalcet; Dietary Supplements; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Parathyroidectomy; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Up-Regulation; Vitamin D | 2015 |
Cinacalcet in pediatric and adolescent chronic kidney disease: a single-center experience.
Topics: Adolescent; Alkaline Phosphatase; Bone Density; Calcimimetic Agents; Child; Child, Preschool; Cinacalcet; Drug Monitoring; Female; Humans; Hyperparathyroidism, Secondary; Infant; Kidney; Kidney Function Tests; Male; Naphthalenes; Parathyroid Hormone; Patient Acuity; Practice Guidelines as Topic; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic; Saudi Arabia; Treatment Outcome; Ultrasonography | 2015 |
TREATMENT WITH CINACALCET INCREASES PLASMA ADIPONECTIN CONCENTRATION IN HEMODIALYZED PATIENTS WITH CHRONIC KIDNEY DISEASE AND SECONDARY HYPERPARATHYROIDISM.
Topics: Adiponectin; Calcimimetic Agents; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Interleukin-6; Male; Middle Aged; Parathyroid Hormone; Renal Dialysis; Renal Insufficiency, Chronic | 2015 |
Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement.
Topics: Cinacalcet; Clinical Trials as Topic; Europe; Humans; Hyperparathyroidism, Secondary; Meta-Analysis as Topic; Naphthalenes; Nephrology; Phosphates; Renal Insufficiency, Chronic; Societies, Medical; Sterols; Treatment Outcome; Vitamin D | 2015 |
Importance of abnormal bone metabolism in the acceleration of atherosclerosis in hemodialysis patients.
Topics: Atherosclerosis; Bone Resorption; Calcimimetic Agents; Calcium; Cinacalcet; Disease Progression; Humans; Phosphates; Renal Dialysis; Renal Insufficiency, Chronic; Vascular Calcification | 2015 |
Efficacy and safety of body weight-adapted oral cholecalciferol substitution in dialysis patients with vitamin D deficiency.
Topics: Administration, Oral; Aged; Aged, 80 and over; Body Weight; Calcifediol; Calcimimetic Agents; Calcitriol; Calcium; Cholecalciferol; Cinacalcet; Drug Dosage Calculations; Drug Substitution; Female; Humans; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic; Vitamin D Deficiency; Vitamins | 2015 |
Changes of Serum Total and Free Testosterone Concentrations in Male Chronic Hemodialysis Patients with Secondary Hyperparathyroidism in Response to Cinacalcet Treatment.
Topics: Adult; Aged; Biomarkers; Calcimimetic Agents; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic; Testosterone | 2016 |
Evaluation of Parathyroidectomy for Secondary and Tertiary Hyperparathyroidism by the Parathyroid Surgeons' Society of Japan.
Topics: Adult; Aged; Calcimimetic Agents; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Japan; Male; Middle Aged; Outcome and Process Assessment, Health Care; Parathyroidectomy; Postoperative Complications; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies | 2016 |
[Treatment of secondary hyperparathyroidism in hemodialysed patients--paricalcitol with or without cinacalcet].
Topics: Adult; Aged; Cinacalcet; Drug Therapy, Combination; Ergocalciferols; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Parathyroid Hormone; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome | 2016 |
Effectiveness of Cinacalcet in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Not Receiving Dialysis.
Topics: Aged; Aged, 80 and over; Calcimimetic Agents; Calcium; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Off-Label Use; Parathyroid Hormone; Phosphorus; Renal Insufficiency, Chronic; Retrospective Studies; Treatment Outcome | 2016 |
Analysis of the kinetics of the parathyroid hormone, and of associated patient outcomes, in a cohort of haemodialysis patients.
Topics: Adult; Aged; Aged, 80 and over; Calcium; Cinacalcet; Dialysis Solutions; Female; Humans; Hydroxycholecalciferols; Inflammation; Kinetics; Male; Malnutrition; Middle Aged; Parathyroid Hormone; Parathyroidectomy; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic; Survival Rate | 2016 |
Management of secondary hyperparathyroidism: practice patterns and outcomes of cinacalcet treatment with or without active vitamin D in Austria and Switzerland - the observational TRANSIT Study.
Topics: Adult; Aged; Aged, 80 and over; Austria; Calcimimetic Agents; Causality; Cinacalcet; Comorbidity; Drug Therapy, Combination; Female; Humans; Hyperparathyroidism, Secondary; Longitudinal Studies; Male; Middle Aged; Practice Patterns, Physicians'; Prevalence; Renal Insufficiency, Chronic; Risk Factors; Switzerland; Treatment Outcome; Vitamin D | 2017 |
Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease.
Topics: Animals; Biomarkers; Bone Resorption; Calcitriol; Calcium; Cinacalcet; Creatinine; Disease Models, Animal; Ergocalciferols; Female; Fibroblast Growth Factors; Hyperparathyroidism; Hyperphosphatemia; Hypocalcemia; Naphthalenes; Nephrectomy; Parathyroid Hormone; Phosphorus; Rats; Rats, Sprague-Dawley; Receptors, Calcium-Sensing; Renal Insufficiency, Chronic; Severity of Illness Index; Tibia; Uremia | 2010 |
Do calcimimetics directly alter bone remodeling?
Topics: Animals; Biomarkers; Bone Remodeling; Bone Resorption; Calcitriol; Cinacalcet; Ergocalciferols; Fibroblast Growth Factors; Humans; Hyperparathyroidism; Hyperphosphatemia; Hypocalcemia; Naphthalenes; Parathyroid Hormone; Rats; Renal Insufficiency, Chronic; Severity of Illness Index; Tibia; Treatment Outcome; Uremia | 2010 |
Cinacalcet and cardiovascular mortality in hemodialysis patients.
Topics: Calcimimetic Agents; Cardiovascular Diseases; Cinacalcet; Humans; Naphthalenes; Receptors, Calcium-Sensing; Renal Dialysis; Renal Insufficiency, Chronic | 2010 |
Economic evaluation of cinacalcet in the treatment of secondary hyperparathyroidism in Italy.
Topics: Adult; Aged; Cinacalcet; Computer Simulation; Cost-Benefit Analysis; Decision Support Techniques; Decision Trees; Female; Humans; Hyperparathyroidism, Secondary; Italy; Life Expectancy; Male; Markov Chains; Middle Aged; Models, Statistical; Naphthalenes; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Risk Factors; Treatment Outcome | 2010 |
Short-term use of cinacalcet in children on regular hemodialysis.
Topics: Adolescent; Calcimimetic Agents; Child; Cinacalcet; Female; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Hyperphosphatemia; Male; Naphthalenes; Parathyroid Hormone; Renal Dialysis; Renal Insufficiency, Chronic | 2012 |
Pharmacological control of secondary hyperparathyroidism in hemodialysis subjects: a cost consequences analysis of data from the FARO study.
Topics: Aged; Aged, 80 and over; Calcitriol; Cinacalcet; Comorbidity; Cost-Benefit Analysis; Drug Therapy, Combination; Ergocalciferols; Fees, Pharmaceutical; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Renal Dialysis; Renal Insufficiency, Chronic | 2012 |
Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: results from the MBD-5D study.
Topics: Aged; Biomarkers; Bone Diseases, Metabolic; Calcimimetic Agents; Calcium; Cinacalcet; Drug Prescriptions; Drug Utilization; Drug Utilization Review; Female; Humans; Hyperparathyroidism, Secondary; Japan; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Practice Patterns, Physicians'; Prevalence; Prospective Studies; Receptors, Calcitriol; Renal Dialysis; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome; Vitamin D | 2012 |
Effects of cinacalcet on bone mineral density and bone markers in hemodialysis patients with secondary hyperparathyroidism.
Topics: Absorptiometry, Photon; Aged; Alkaline Phosphatase; Biomarkers; Bone Density; Calcimimetic Agents; Cinacalcet; Female; Femur Neck; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Regression Analysis; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies; Time Factors; Treatment Outcome | 2013 |
Hyperparathyroidism in chronic kidney disease: complexities within the commonplace.
Topics: Adult; Aged; Cinacalcet; Comorbidity; Female; Humans; Hypercalcemia; Hyperparathyroidism; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Renal Insufficiency, Chronic | 2012 |
Withdrawal of cinacalcet at the time of renal transplantation is not a risk factor for allograft calcifications in the early posttransplantation period.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Biopsy; Calcimimetic Agents; Calcinosis; Cinacalcet; Drug Administration Schedule; Female; Humans; Hyperparathyroidism, Secondary; Kidney Transplantation; Male; Middle Aged; Naphthalenes; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies; Risk Assessment; Risk Factors; Spain; Time Factors; Treatment Outcome; Young Adult | 2012 |
Micromethod for quantification of cinacalcet in human plasma by liquid chromatography-tandem mass spectrometry using a stable isotope-labeled internal standard.
Topics: Adult; Calcimimetic Agents; Child; Chromatography, Liquid; Cinacalcet; Clinical Trials as Topic; Drug Monitoring; Humans; Hyperparathyroidism; Isotope Labeling; Microchemistry; Naphthalenes; Pilot Projects; Quality Control; Reference Standards; Renal Dialysis; Renal Insufficiency, Chronic; Reproducibility of Results; Tandem Mass Spectrometry | 2013 |
Cinacalcet chloride is efficient and safe in renal transplant recipients with posttransplant hyperparathyroidism.
Topics: Calcium; Cinacalcet; Female; Follow-Up Studies; Humans; Hyperparathyroidism, Secondary; Kidney Transplantation; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphates; Postoperative Complications; Renal Insufficiency, Chronic; Safety | 2006 |